Dermatology Drugs Market Research Report: By Treatment (Topical Corticosteroids, Retinoids, Biologics, Calcineurin Inhibitors, Antihistamines, Hormone Therapy), Drug (Humira, Remicade, Otezla, Stelara, Enbrel, Cosentyx, Neoral, Taltz, Cubicin, Canesten, Zyvox, Dupixent, Protopic, Valtrex, Eucrisa), Prescription Mode (Prescription Drugs, Over-the-Counter Drugs), Therapy Area (Psoriasis, Atopic Dermatitis, Acne, Rosacea, Skin Cancer, Scar), Distribution Channel (Direct, Wholesale/Retail), End User (Hospitals, Clinics, Cosmetic centers, At-home) - Global Industry Analysis and Growth Forecast to 2030

Chapter 1. Research Background

1.1 Research Objectives

1.2 Market Definition

1.3 Research Scope

1.3.1 Market Segmentation by Treatment

1.3.2 Market Segmentation by Drug

1.3.3 Market Segmentation by Prescription Mode

1.3.4 Market Segmentation by Therapy Area

1.3.5 Market Segmentation by Distribution Channel

1.3.6 Market Segmentation by End User

1.3.7 Market Segmentation by Region

1.3.8 Analysis Period

1.3.9 Market Data Reporting Unit

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1 Breakdown of Primary Research Respondents

2.2.1.1 By region

2.2.1.2 By industry participant

2.2.1.3 By company type

2.3 Market Size Estimation

2.4 Data Triangulation

2.5 Currency Conversion Rates

2.6 Assumptions for the Study

Chapter 3. Executive Summary

Chapter 4. Introduction

4.1 Definition of Market Segments

4.1.1 By Treatment

4.1.1.1 Topical corticosteroids

4.1.1.2 Retinoids

4.1.1.3 Biologics

4.1.1.4 Calcineurin inhibitors

4.1.1.5 Antihistamines

4.1.1.6 Hormone therapy

4.1.1.7 Others

4.1.2 By Drug

4.1.2.1 Humira

4.1.2.2 Remicade

4.1.2.3 Otezla

4.1.2.4 Stelara

4.1.2.5 Enbrel

4.1.2.6 Cosentyx

4.1.2.7 Neoral

4.1.2.8 Taltz

4.1.2.9 Cubicin

4.1.2.10 Canesten

4.1.2.11 Zyvox

4.1.2.12 Dupixent

4.1.2.13 Protopic

4.1.2.14 Valtrex

4.1.2.15 Eucrisa

4.1.2.16 Others

4.1.3 By Prescription Mode

4.1.3.1 Prescription drugs

4.1.3.2 OTC drugs

4.1.4 By Therapeutic Area

4.1.4.1 Psoriasis

4.1.4.2 Atopic dermatitis

4.1.4.3 Acne

4.1.4.4 Rosacea

4.1.4.5 Skin cancer

4.1.4.6 Scar

4.1.4.7 Others

4.1.5 By Distribution Channel

4.1.5.1 Direct

4.1.5.2 Wholesale/retail

4.1.5.3 Online

4.1.6 By End User

4.1.6.1 Hospitals

4.1.6.2 Clinics

4.1.6.3 Cosmetic centers

4.1.6.4 At-home

4.1.6.5 Others

4.2 Market Dynamics

4.2.1 Trends

4.2.1.1 Product approvals

4.2.2 Drivers

4.2.2.1 Rising geriatric population

4.2.2.2 Increasing incidence of dermatological diseases

4.2.2.3 Growing awareness on skin diseases

4.2.2.4 Increasing personal care spending

4.2.2.5 Strong pipeline of dermatological drugs

4.2.2.6 Impact analysis of drivers on market forecast

4.2.3 Restraints

4.2.3.1 Patent expiry and generic drug development

4.2.3.2 Side-effects of certain classes of therapeutic drugs

4.2.3.3 Impact analysis of restraints on market forecast

4.2.4 Opportunities

4.2.4.1 Huge potential in emerging markets

4.3 Impact of COVID-19

4.4 Porter’s Five Forces Analysis

Chapter 5. Global Market Size and Forecast

5.1 Overview

5.2 By Treatment

5.3 By Drug

5.4 By Prescription Mode

5.5 By Therapy Area

5.5.1 Psoriasis Drugs Market, by Prescription Mode

5.5.2 Atopic Dermatitis Drugs Market, by Prescription Mode

5.5.3 Acne Drugs Market, by Prescription Mode

5.5.4 Rosacea Drugs Market, by Prescription Mode

5.5.5 Scar Drugs Market, by Prescription Mode

5.5.6 Skin Cancer Drugs Market, by Prescription Mode

5.6 By Distribution Channel

5.7 By End User

5.8 By Region

Chapter 6. North America Market Size and Forecast

6.1 Overview

6.2 By Treatment

6.3 By Prescription Mode

6.4 By Therapy Area

6.4.1 Psoriasis Drugs Market, by Prescription Mode

6.4.2 Atopic Dermatitis Drugs Market, by Prescription Mode

6.4.3 Acne Drugs Market, by Prescription Mode

6.4.4 Rosacea Drugs Market, by Prescription Mode

6.4.5 Scar Drugs Market, by Prescription Mode

6.4.6 Skin Cancer Drugs Market, by Prescription Mode

6.5 By Distribution Channel

6.6 By End User

6.7 By Country

6.7.1 U.S. Dermatology Drugs Market

6.7.1.1 By treatment

6.7.1.2 By distribution channel

6.7.2 Canada Dermatology Drugs Market

6.7.2.1 By treatment

6.7.2.2 By distribution channel

Chapter 7. Europe Market Size and Forecast

7.1 Overview

7.2 By Treatment

7.3 By Prescription Mode

7.4 By Therapy Area

7.4.1 Psoriasis Drugs Market, by Prescription Mode

7.4.2 Atopic Dermatitis Drugs Market, by Prescription Mode

7.4.3 Acne Drugs Market, by Prescription Mode

7.4.4 Rosacea Drugs Market, by Prescription Mode

7.4.5 Scar Drugs Market, by Prescription Mode

7.4.6 Skin Cancer Drugs Market, by Prescription Mode

7.5 By Distribution Channel

7.6 By End User

7.7 By Country

7.7.1 Germany Dermatology Drugs Market

7.7.1.1 By treatment

7.7.1.2 By distribution channel

7.7.2 France Dermatology Drugs Market

7.7.2.1 By treatment

7.7.2.2 By distribution channel

7.7.3 U.K. Dermatology Drugs Market

7.7.3.1 By treatment

7.7.3.2 By distribution channel

7.7.4 Italy Dermatology Drugs Market

7.7.4.1 By treatment

7.7.4.2 By distribution channel

7.7.5 Spain Dermatology Drugs Market

7.7.5.1 By treatment

7.7.5.2 By distribution channel

Chapter 8. APAC Market Size and Forecast

8.1 Overview

8.2 By Treatment

8.3 By Prescription Mode

8.4 By Therapy Area

8.4.1 Psoriasis Drugs Market, by Prescription Mode

8.4.2 Atopic Dermatitis Drugs Market, by Prescription Mode

8.4.3 Acne Drugs Market, by Prescription Mode

8.4.4 Rosacea Drugs Market, by Prescription Mode

8.4.5 Scar Drugs Market, by Prescription Mode

8.4.6 Skin Cancer Drugs Market, by Prescription Mode

8.5 By Distribution Channel

8.6 By End User

8.7 By Country

8.7.1 Japan Dermatology Drugs Market

8.7.1.1 By treatment

8.7.1.2 By distribution channel

8.7.2 China Dermatology Drugs Market

8.7.2.1 By treatment

8.7.2.2 By distribution channel

8.7.3 India Dermatology Drugs Market

8.7.3.1 By treatment

8.7.3.2 By distribution channel

Chapter 9. LATAM Market Size and Forecast

9.1 Overview

9.2 By Treatment

9.3 By Prescription Mode

9.4 By Therapy Area

9.4.1 Psoriasis Drugs Market, by Prescription Mode

9.4.2 Atopic Dermatitis Drugs Market, by Prescription Mode

9.4.3 Acne Dermatology Drugs Market, by Prescription Mode

9.4.4 Rosacea Drugs Market, by Prescription Mode

9.4.5 Scar Drugs Market, by Prescription Mode

9.4.6 Skin Cancer Drugs Market, by Prescription Mode

9.5 By Distribution Channel

9.6 By End User

9.7 By Country

Chapter 10. MEA Market Size and Forecast

10.1 Overview

10.2 By Treatment

10.3 By Prescription Mode

10.4 By Therapy Area

10.4.1 Psoriasis Drugs Market, by Prescription Mode

10.4.2 Atopic Dermatitis Drugs Market, by Prescription Mode

10.4.3 Acne Drugs Market, by Prescription Mode

10.4.4 Rosacea Drugs Market, by Prescription Mode

10.4.5 Scar Drugs Market, by Prescription Mode

10.4.6 Skin Cancer Drugs Market, by Prescription Mode

10.5 By Distribution Channel

10.6 By End User

10.7 By Country

Chapter 11. Competitive Landscape

11.1 Product Benchmarking of Key Players

11.2 Strategic Developments

11.2.1 Product Launches and Approvals

11.2.2 Acquisitions

11.2.3 Other Developments

Chapter 12. Company Profiles

12.1 Bausch Health Companies Inc.

12.1.1 Business Overview

12.1.2 Product and Service Offerings

12.1.3 Key Financial Summary

12.2 Novartis AG

12.2.1 Business Overview

12.2.2 Product and Service Offerings

12.2.3 Key Financial Summary

12.3 Pfizer Inc.

12.3.1 Business Overview

12.3.2 Product and Service Offerings

12.3.3 Key Financial Summary

12.4 Bristol-Myers Squibb Company

12.4.1 Business Overview

12.4.2 Product and Service Offerings

12.4.3 Key Financial Summary

12.5 Johnson & Johnson

12.5.1 Business Overview

12.5.2 Product and Service Offerings

12.5.3 Key Financial Summary

12.6 Merck & Co. Inc.

12.6.1 Business Overview

12.6.2 Product and Service Offerings

12.6.3 Key Financial Summary

12.7 Amgen Inc.

12.7.1 Business Overview

12.7.2 Product and Service Offerings

12.7.3 Key Financial Summary

12.8 AbbVie Inc.

12.8.1 Business Overview

12.8.2 Product and Service Offerings

12.8.3 Key Financial Summary

12.9 Eli Lilly and Company

12.9.1 Business Overview

12.9.2 Product and Service Offerings

12.9.3 Key Financial Summary

12.10 Galderma S.A.

12.10.1 Business Overview

12.10.2 Product and Service Offerings

12.11 GlaxoSmithKline plc

12.11.1 Business Overview

12.11.2 Product and Service Offerings

12.11.3 Key Financial Summary

12.12 Mylan N.V.

12.12.1 Business Overview

12.12.2 Product and Service Offerings

12.12.3 Key Financial Summary

12.13 LEO Pharma A/S

12.13.1 Business Overview

12.13.2 Product and Service Offerings

12.13.3 Key Financial Summary

12.14 Sanofi

12.14.1 Business Overview

12.14.2 Product and Service Offerings

12.14.3 Key Financial Summary

Chapter 13. Appendix

13.1 Abbreviations

13.2 Sources and References

13.3 Related Reports

 

List of Tables

 

TABLE 1 ANALYSIS PERIOD OF THE STUDY

TABLE 2 PIPELINE DRUGS FOR TREATMENT OF ACNE

TABLE 3 PIPELINE DRUGS FOR TREATMENT OF ACTINIC KERATOSIS

TABLE 4 DRIVERS FOR THE MARKET: IMPACT ANALYSIS

TABLE 5 PATENT EXPIRATION OF DERMATOLOGY DRUGS

TABLE 6 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS

TABLE 7 GLOBAL DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2019–2024)

TABLE 8 GLOBAL DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2025–2030)

TABLE 9 GLOBAL DERMATOLOGY DRUGS MARKET, BY DRUG, $M (2019–2024)

TABLE 10 GLOBAL DERMATOLOGY DRUGS MARKET, BY DRUG, $M (2025–2030)

TABLE 11 GLOBAL DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2019–2024)

TABLE 12 GLOBAL DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2025–2030)

TABLE 13 GLOBAL DERMATOLOGY DRUGS MARKET, BY THERAPY AREA, $M (2019–2024)

TABLE 14 GLOBAL DERMATOLOGY DRUGS MARKET, BY THERAPY AREA, $M (2025–2030)

TABLE 15 GLOBAL PSORIASIS DRUGS MARKET, BY PRESCRIPTION MODE, $M (2019–2024)

TABLE 16 GLOBAL PSORIASIS DRUGS MARKET, BY PRESCRIPTION MODE, $M (2025–2030)

TABLE 17 GLOBAL ATOPIC DERMATITIS DRUGS MARKET, BY PRESCRIPTION MODE, $M (2019–2024)

TABLE 18 GLOBAL ATOPIC DERMATITIS DRUGS MARKET, BY PRESCRIPTION MODE, $M (2025–2030)

TABLE 19 GLOBAL ACNE DRUGS MARKET, BY PRESCRIPTION MODE, $M (2019–2024)

TABLE 20 GLOBAL ACNE DRUGS MARKET, BY PRESCRIPTION MODE, $M (2025–2030)

TABLE 21 GLOBAL ROSACEA DRUGS MARKET, BY PRESCRIPTION MODE, $M (2019–2024)

TABLE 22 GLOBAL ROSACEA DRUGS MARKET, BY PRESCRIPTION MODE, $M (2025–2030)

TABLE 23 GLOBAL SCAR DRUGS MARKET, BY PRESCRIPTION MODE, $M (2019–2024)

TABLE 24 GLOBAL SCAR DRUGS MARKET, BY PRESCRIPTION MODE, $M (2025–2030)

TABLE 25 GLOBAL SKIN CANCER DRUGS MARKET, BY PRESCRIPTION MODE, $M (2019–2024)

TABLE 26 GLOBAL SKIN CANCER DRUGS MARKET, BY PRESCRIPTION MODE, $M (2025–2030)

TABLE 27 GLOBAL DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2019–2024)

TABLE 28 GLOBAL DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2025–2030)

TABLE 29 GLOBAL DERMATOLOGY DRUGS MARKET, BY END USER, $M (2019–2024)

TABLE 30 GLOBAL DERMATOLOGY DRUGS MARKET, BY END USER, $M (2025–2030)

TABLE 31 GLOBAL DERMATOLOGY DRUGS MARKET, BY REGION, $M (2019–2024)

TABLE 32 GLOBAL DERMATOLOGY DRUGS MARKET, BY REGION, $M (2025–2030)